Keyphrases
Comparative Efficacy
100%
Comparative Safety
100%
Ankylosing Spondylitis
100%
Secukinumab
100%
Ixekizumab
100%
Response Rate
71%
Odds Ratio
57%
Credible Interval
42%
Adalimumab
42%
No Significant Difference
28%
Serious Adverse Events
28%
Surface under the Cumulative Ranking Curve
28%
ASAS40
28%
Objective Evaluation
14%
Placebo Groups
14%
Placebo
14%
% Response
14%
High Probability
14%
Effectiveness Evaluation
14%
Randomized Controlled Trial
14%
Direct Data
14%
Network Meta-analysis
14%
Indirect Data
14%
Assessment of SpondyloArthritis International Society
14%
Bayesian Credible Interval
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ankylosing Spondylitis
100%
Secukinumab
100%
Ixekizumab
100%
Adalimumab
42%
Adverse Event
28%
Placebo
28%
Randomized Controlled Trial
14%
Spondylarthritis
14%
Immunology and Microbiology
Ankylosing Spondylitis
100%
Secukinumab
100%
Ixekizumab
100%
Adalimumab
42%